Avascular Necrosis of the TalusTalar Osteochondral Defect of AnkleTalar Dysfunction
Investigational drug(s) / intervention(s)
Total Talus Replacement (TTR)
Total Talus Replacement (TTR): The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
Study summary
This is a Humanitarian Device Exemption (HDE) approved device. The purpose of this study is to evaluate the continued safety and probable benefit of the restor3d Total Talus Replacement device in commercial use.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* ≥22 Years of Age
* Scheduled to receive TTR implant for one of the following indications:
* Avascular necrosis of the talus
* Avascular necrosis of the talus in addition to talar collapse, cysts or non-union
* Large, uncontained, unstable, or cystic talar osteochondral defects with risk of collapse or talar osteochondral defects not responsive to traditional treatments
* Nonunion following talar fracture or talar extrusion, unresponsive to more conservative treatments
* Have not had a prior Total Talus Replacement device implanted
* Not planning to receive bilateral Total Talus Replacement devices
* Subject signs a written informed consent form (ICF) prior to the surgical procedure
Exclusion Criteria:
* Surgical procedures other than those listed in the indications for use.
* Use of implant greater than 6 months from date of patient's preoperative CT scan.
* Degenerative changes in the tibiotalar, subtalar or talonavicular joints.
* Gross deformity in sagittal or coronal planes. More than 15 degrees of varus or valgus deformity in the coronal plane, or more than 50% subluxation anteriorly or posteriorly of the talus in the sagittal plane
* Patients with an active local or systemic infection.
* Osteonecrosis of the calcaneus, distal tibia or navicular.
* Known history of existing malignancy, or any systemic infection, local infection, or skin compromise at the surgical site.
* Blood supply limitations and previous infections that may prevent healing.
* Physical conditions that would eliminate adequate implant support or prevent healing, including inadequate soft tissue coverage.
* Conditions which may limit the patient's ability or willingness to restrict activities or follow directions postoperatively during the healing period.
* Presence of neurological deficit which would prevent patient postoperative compliance.
* Patients with foreign body sensitivity, suspected or documented material allergy or intolerance. Where material sensitivity is suspected, appropriate tests should be conducted, and sensitivity ruled out prior to implantation.
Primary outcome measure(s)
Proportion of participants who pass a composite of safety and probable benefit outcomes — At 5 years compared to baseline The primary endpoint for this post approval study is a composite of safety and probable benefit.
The safety endpoint is defined by the absence of device-related SAE and subsequent secondary surgical intervention (SSSI) on the affected joints.
The probable benefit endpoint is defined as joint salvage with the restor3d device still in place.
This composite endpoint will be evaluated by determining the proportion of patients who do not have a device-related SAE or SSSI, AND have the restor3d implant in place at 5 years.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.